TranScrip Oncology

TranScrip has built a strong oncology business spanning a wide range of phases of development, indications and geographic locations. TranScrip has conducted many contracts and oncology accounts for a substantial proportion of its recent revenue. These contracts include supporting a major successful NDA and MAA submission, global medical monitoring for phase III studies and a wide range of expert services on portfolio planning and drug development.

Additional therapeutic areas

Infectious Diseases, Respiratory, Internal Medicine, CNS/Pain


TranScrip Oncology Experts

TranScrip's Oncology group fields bespoke teams or individuals with depth and breadth of experience in oncology and immunology to meet your needs, solve problems and differentiate you from the competition. We cover all aspects of drug development from translational science through to registration and medical affairs, and covering all mechanisms including targeted therapy, immunotherapy and vaccines and novel cytotoxics.

Linda Summerton
Head of Oncology

Linda brings to her role as Head of the Oncology Team a wealth of experience obtained from over 25 years in the global pharmaceutical industry, with particular depth and breadth in the oncology arena. Working for AstraZeneca, she was initially Project Director for Iressa® in first registrations, and latterly Head of Strategy and Portfolio for the Oncology and Infection Therapy Area Management Team. She was also SVP Portfolio and Project Integration (PPI) at Merck KGaA, leading the portfolio steering committee for oncology development programmes. Now with TranScrip, she is leading clinical development, registration and medical affairs programmes in Oncology.

Latest Oncology News

19 September

ESMO 2017 Facts and Figures

TranScrip Senior Partners, Linda Summerton, Paul Branthwaite and Ed Currie report on the ESMO (European Society for Medical Oncology) conference in Madrid, 8-12 September 2017.

Forthcoming Events

Company Product Phase Indication and Service
Top 50 VEGF TK Inhibitor Launch Renal Cell Carcinoma: Medical affairs for renal cell carcinoma programme.
Top 50 Pi3 Kinase Inhibitor Translational Non Hodgkin's Lymphoma: DDI Interactions and risk profile for potential toxicity for combinations of PI3K inhibitors in Non Hodgkin's Lymphoma.
Medium Novel Angiogenesis Inhibitor Phase III Prostate Cancer: Director PV oncology, safety services including all narrative review, oversight of all AEs from clincal trial programme medical affairs and training information for MSLs for programme in castrate resistant prostate cancer.
CRO Immunotherapy Phase III Glioblastoma: Global responsibility for medical monitoring for glioblastoma programme.
CRO TK3 Inhibtor Phase III Acute Myeloid Leukaemia: Global responsibility for medical monitoring for acute myeloid leukaemia programme.
Top 50 Various Translational Various: Project Director for oversight including preparation of TPPs and development plans.
Top 50 Various Big pharma portfolio Various: Support for development and commercialisation, review of data and regulatory submissions, generation of project-related documentation and submissions.
Top 50 Monoclonal Antibody Mature Breast Cancer: Pharmacovigilance and regulatory responsibilities for the MAAs and NDAs for breast cancer.
SME HDAC Inhibitor Translational Prostate Cancer: Clinical development and regulatory affairs support prostate cancer.
SME Anticancer Vaccine Translational Melanoma: Ad hoc oncology advice in melanoma.
SME Cytotoxic Conjugate Clinical development Various: Development of reformulation of established compounds as conjugates for the treatment of cancers.